Type 1 Diabetes Study Enrolls First Participant at Spectrum Clinical Research

Spectrum Clinical Research has achieved a significant milestone with the enrollment of the first participant in their groundbreaking Type 1 Diabetes Study. This study holds immense promise for millions living with this chronic condition.

The research is currently seeking adolescents between the ages of 11 and 17 with Type 1 diabetes. This is an exciting opportunity for young people to contribute to the fight against Type 1 diabetes, while potentially benefiting from the latest research advancements.  

Raising Awareness

This study not only represents a significant milestone for Spectrum Clinical Research, but also serves to raise awareness about Type 1 diabetes and the challenges faced by adolescents living with the condition.

Who can participate?

The study is seeking participants who were recently diagnosed with Type 1 Diabetes (within the past two years) and are between the ages of 11 and 17.

What is being studied?

The study will evaluate a modified starch called HAMS-AB to see if it impacts insulin production and gut bacteria in people with newly diagnosed Type 1 Diabetes. HAMS-AB is a dietary fiber that has shown promise in early research.

This is an exciting opportunity for adolescents with Type 1 diabetes to contribute to advancements in diabetes care while potentially experiencing the benefits of this novel treatment themselves. If you or someone you know is interested in participating in this study, please contact Spectrum Clinical Research for more information.